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Open access under CC BYAdvances in high throughput and high content (HT/HC) methods such as those used in the ﬁelds of tox-
icogenomics, bioinformatics, and computational toxicology have the potential to improve both the efﬁ-
ciency and effectiveness of toxicity evaluations and risk assessments. However, prior to use, scientiﬁc
conﬁdence in these methods should be formally established. Traditional validation approaches that
deﬁne relevance, reliability, sensitivity and speciﬁcity may not be readily applicable. HT/HC methods
are not exact replacements for in vivo testing, and although run individually, these assays are likely to
be used as a group or battery for decision making and use robotics, which may be unique in each labo-
ratory setting. Building on the frameworks developed in the 2010 Institute of Medicine Report on Bio-
markers and the OECD 2007 Report on (Q)SAR Validation, we present constructs that can be adapted
to address the validation challenges of HT/HC methods. These are ﬂexible, transparent, and require expli-
cit speciﬁcation of context and purpose of use such that scientiﬁc conﬁdence (validation) can be deﬁned
to meet different regulatory applications. Using these constructs, we discuss how anchoring the assays
and their prediction models to Adverse Outcome Pathways (AOPs) could facilitate the interpretation of
results and support scientiﬁcally defensible ﬁt-for-purpose applications.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
In 2007, the National Research Council released a report enti-
tled Toxicity Testing in the 21st Century: A Vision and A Strategy
(TT21C) (NRC, 2007). The ‘‘Strategy’’ in the title refers to the path
forward for increasing the use of in vitro high throughput and high
content (HT/HC) assays and computational methods in lieu of ani-
mal bioassays for safety evaluations, and, should animal testing be
required, the approach would indicate the types of studies and
endpoints for which in vivo tests are absolutely needed. This paper
and the continuing effort to support TT21C is a response to: (1) the
advances in understanding the molecular and cellular events
responsible for toxicity; (2) the desire to reﬁne, reduce and replace
the use of animals in regulatory toxicity testing; and (3) the desire
to provide more complete toxicity evaluations for the large num-
ber of chemicals in commercial use—an effort that would be prac-
tically impossible to achieve using traditional animal testing
methods.icz).
-NC-ND license.In vitro and computational approaches have the potential to im-
prove and inform science-based health assessments for a broad
range of chemicals. A successful transition is dependent on use of
assays and prediction models for identifying relevant human
health outcomes, with a deﬁned degree of conﬁdence. Initially
for prioritization and screening of chemicals and, potentially in
the future, for hazard prediction, the evaluation will include com-
parisons to the current animal testing framework and the context
for predictive use of these traditional in vivo data. Thus, in addition
to research to develop and establish scientiﬁc conﬁdence in
speciﬁc HT/HC methods, a transformation in the testing and eval-
uation framework itself is needed to assure integration and appro-
priate use of these new and emerging data for decision making.
Integrated testing is envisioned to replace the traditional use of a
sequential toxicity testing battery with an evaluation system that
takes into account data and information from a variety of sources,
including mode of action (MOA), biological proﬁling using in silico
and in vitro methods, and exposure information as well. In this
manner, knowledge gained from biological proﬁling can be used
for initial hazard characterization, and any testing in animal
models will be comprised of speciﬁc studies needed to characterize
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certainty.
Conﬁdence in biological proﬁling methods is key to their appli-
cation. Thus, there must be an adequate understanding of the
validity of these methods and prediction models—the relevance,
reliability, sensitivity, and speciﬁcity of the assays. The associated
computational proﬁling methods need to be established so that
regulatory agencies, the regulated community, and the public can
be assured that the use of this knowledge for decision making is
scientiﬁcally sound.
While there are signiﬁcant challenges in establishing scientiﬁc
conﬁdence in new HT/HC methods, many of the elements of tradi-
tional validation process (NIEHS, 1997) can still be used. These
include:
 a speciﬁc description of the scientiﬁc and regulatory rationales
and the speciﬁc purpose of the method (how the results will be
used in decision making);
 the relationship of the test endpoint(s) to the biologic effect of
interest;
 a detailed protocol for the test system (including materials,
methods of measurement and data analysis procedures);
 structural/physical–chemical domains of applicability;
 criteria for data interpretation (the prediction model);
 description of the known limitations of the method; and
 standards and procedures to be followed to ascertain the
method is properly performing (e.g., positive and negative stan-
dards to be included in each run).
However, two key elements of the traditional test method vali-
dation process can be lacking in certain HT/HC methods. When HT/
HC test methods and batteries, such as those which utilize proprie-
tary methods or one-of-a-kind robotic systems, traditional inter-
laboratory validation is not achievable, and thus reproducibility
of results cannot be independently veriﬁed. Furthermore, for many
proprietary methods, the data used to develop the prediction mod-
els are also proprietary and are not publicly available—this means
the traditional approach for independent scientiﬁc peer review of
prediction models cannot be employed. Validation of HT/HC meth-
ods is also impacted by the rapid pace at which new methods are
being developed and reﬁned, and the desire to use the newest
methods as soon as practically possible. However, these limitations
do not negate the need for addressing these elements of validation/
evaluation so as to garner the required scientiﬁc conﬁdence in the
performance of these test methods and prediction models. These
elements cannot simply be ignored, but instead should be recog-
nized as technical and policy challenges that need to be addressed.
This paper provides a conceptual discussion of the level of
knowledge needed to apply HT/HC methods for the purposes of
(1) prioritization, (2) screening, and (3) hazard prediction. We then
suggest frameworks for validation that should be considered to ad-
dress the challenges noted above. The purpose is to provide food-
for-thought with the goal of stimulating further scientiﬁc dialog
on this important topic (Stephens et al., 2011, 2013; Judson
et al., in press).2. Anchoring HT/HC methods and prediction models to adverse
effects/adverse responses
The vision of 21st century toxicity testing includes the concept
of ‘‘toxicity pathways’’ (NRC, 2007). These are cellular response
pathways, that, when sufﬁciently perturbed, are expected to result
in adverse health effects. An adverse effect is deﬁned as ‘‘a change
in morphology, physiology, growth, development, reproduction, or
life span of a cell or organism, system, or (sub)population thatresults in an impairment of functional capacity, an impairment of
the capacity to compensate for additional stress, or an increase in
susceptibility to other inﬂuences’’, as deﬁned in a recent ILSI/HESI
workshop (Keller et al., 2012). In the vision presented by the NRC
panel (NRC, 2007), low exposures could cause small perturbations
that do not lead to any alterations in normal biological functions
whatsoever. Higher exposures could lead to adaptive responses,
which do not necessarily compromise cellular or organ functions.
However, with sufﬁciently large exposures, perturbations could
be great enough to produce cellular injury and adverse effects
(Slikker et al., 2004).
Ankley et al. (2010) broadened the scope of toxicity pathways to
deﬁne the broader construct of adverse outcome pathway (AOP) as
representing ‘‘existing knowledge concerning the linkage between
the molecular initiating event (MIE) and an adverse outcome at the
individual or population level.’’ As such, an AOP is intended to span
multiple levels of biological organization, linking the initial point
of chemical–biological interaction within an organism (the MIE)
to the adverse outcome in an organism or population. Therefore
an AOP links, or anchors, an MIE to an adverse outcome through
a series of key events.
2.1. Replacing the term ‘‘Molecular Initiating Event’’ with ‘‘Initial
Molecular Event’’
The term ‘‘Molecular Initiating Event’’ is problematic. Although
a MIE may be the ﬁrst biological response event in the pathway, it
does not necessarily ‘‘initiate’’ a chain of events that automatically
leads to adverse effects.
Even in the area of mutagenesis and carcinogenesis, the initiat-
ing event is ﬁxation of a mutation in DNA, and not the initial
molecular event of a chemical reacting with DNA or even adduct
formation. Mutations are the result of improper DNA repair follow-
ing a damage event and result in DNA base sequence changes (Gor-
bunova et al., 2007; Preston et al., 2010). For a number of years,
DNA damage/genotoxicity has been linked incorrectly in the minds
of many to mutatagenesis; similarly, current thinking indicates
that the occurrence of mutations is also less clearly associated with
the induction of cancer than previously believed (USEPA, 2007;
Hanahan and Weinberg, 2000, 2011).
A mutation is a heritable change in the DNA base sequence
likely resulting in a different gene product (USEPA, 2007). Histori-
cally, the multistage model for cancer dose response became linked
to the concept of cancer initiation and promotion—the ﬁrst model
stage was ‘‘initiation, the second stage ‘‘promotion’’ and later
stages ‘‘progression.’’ However, neither the multistage model nor
the simplistic initiation–promotion concept of cancer formation
conveys the current biological understanding of carcinogenesis
where it has become clear that tumorigenesis involves ‘‘multiple
rate limiting steps’’ (Hanahan and Weinberg, 2000, 2011).
This potential confusion between the overly simplistic, concept
of ‘‘initiation’’ of cancer and a molecular ‘‘initiating’’ event is a rea-
son for suggesting the term MIE be changed to initial molecular
event (IME). By utilizing the term MIE, the implication is that the
adverse effect is ‘‘initiated’’ by the MIE and inferred by the detec-
tion and measurement of the MIE. This implication creates an
unfortunate opportunity for misunderstanding and misuse of the
MIE within an AOP. For example, in cases where the initial event
is receptor or protein binding, it would be incorrect to interpret
this is the same as an initiating event in either mutagenesis or
carcinogenesis.
There may be a small number of AOPs for which the initial event
is a mutation. Notwithstanding, AOPs for other types of responses
must include elements that address threshold dose and reversibil-
ity. Receptor binding of ligands is reversible and governed by the
law of mass action—whereas a mutation in DNA cannot be
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not stable and can be repaired by repair enzymes. Further, even
in the case of suicide inactivation of an enzyme/protein, there are
threshold doses below which no adverse responses are elicited
(see for example Vandekar et al., 1971) even though reduction in
the activity of the protein moiety can be measured. Thus, as noted,
it would be preferable to replace the termMIE with the term Initial
Molecular Event (IME), because, with the exception perhaps of
site-of-contact toxicants (e.g., corrosives) the ﬁrst event in an
AOP does not trigger or ‘‘initiate’’ a pathological response. An
IME should be considered as a necessary step, but not a sufﬁcient
one, in the process of the discontinuum from exposure to adverse
outcome (see Fig. 1). Hence, we use IME throughout the remainder
of this paper.
2.2. Challenges in deﬁning and using adverse outcome pathways
The key difference between a toxicity pathway (TP) and an AOP
is that a TP is a cellular response pathway whereas an AOP as de-
ﬁned by Ankley et al. (2010) represents a plausible set of connec-
tions leading from the IME to the adverse effect. The AOP is
anchored by the IME and the adverse effect. The level or type of
activity in a cellular response pathway is related to toxicity, but
the mere measurement of any degree of activity in an AOP does
not constitute adversity. For example, what is not yet established
for AOPs is the magnitude, frequency and duration of change in
activities that are necessary to produce adversity. Therefore, mea-
surable changes in activity should not be misinterpreted as demon-
strating a 1:1 relationship between the IME and an adverse effect.
As depicted in Fig. 1, the reality is that there is an ‘‘exposure–ef-
fect discontinuum.’’ The AOP conceptual model ties together
molecular events, cellular responses, organ effects and organismFig. 1. Illustration of the exposure effect discontinuum within the AOP conceptual fra
effects is characterized by overlaying the dose–response relationship upon the AOP fram
the initial molecular event (IME), then proceeds, if magnitude, frequency and duration of
responses, from there to organ effects and from there to adverse effects. At lower doses
stage of the AOP, the dose magnitude/frequency/duration can be too low to trigger transi
the term ‘‘molecular initiating event,’’ the term ‘‘initial molecular event’’ is preferred.and population outcomes through a number of key events, where
the IME is simply the ﬁrst (or one of the ﬁrst) stages of the path-
way. Each key event is a necessary element of the MOA/AOP and
empirically observable (USEPA, 2005; Boobis et al., 2009). To make
the linkage between the IME and the adverse effect, an inherent
assumption to the AOP concept is that an exposure must be at a
sufﬁciently high level and/or duration to exceed the adaptive re-
sponse of an organism. Not all exposures will produce adverse ef-
fects, even when measurable responses are detected in early
events in the pathway (Slikker et al., 2004). Indeed, early key
events are likely interactions with molecular targets or cellular
pathways that fall within the spectrum of adaptive or homeostatic
responses. Key events that occur at higher doses or later in time
may represent reversible toxic effects or physiological repair
mechanisms. At even higher doses or later times, these toxic effects
become irreversible and represent a failure of homeostatic mecha-
nisms and repair processes.
The transition from adaptive/homeostatic mechanisms to repair
mechanisms represents one discontinuum; the transition from
reparable damage to irreparable damage represents a second dis-
continuum (Fig. 1). The speciﬁc combination of the exposure level,
duration of exposure, and homeostatic/repair capacity at which
these transitions occur determines the transition thresholds (Julien
et al., 2009) and variations in homeostatic/repair capacities ac-
count for variations in transition thresholds and indeed, the ob-
served threshold for the apical effect. In general, small or
transient variations in these capacities will be insigniﬁcant in
determining transition thresholds; however, sufﬁciently large
changes in key events will lead to these discontinuities, and these
transitions likely involve large changes in more than one aspect of
the MOA/AOP (Boobis et al., 2009). Understanding dose-related
events and dose-dependent transitions and the duration ofmework. The discontinuous relationship between exposure, response and adverse
ework. The ‘‘discontinuous’’ ﬂow via along the AOP begins with an initial response,
exposure are of sufﬁcient degree at each key event in the AOP, from IME to cellular
, effects may be reversible and although responses may be observed at a particular
tion to the next event in the AOP. (Note: as discussed in the text, although some use
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tion levels will lead to improvements in prediction models based
on AOPs.
Conceptually, TPs and AOPs are in fact biological response path-
ways, and, in general, they are linked or identical to normal re-
sponse pathways that maintain homeostasis and normal function
in the face of both internal and external stressors. Toxicity can be
thought of as failures of homeostasis and resulting maladaptive
and biologically inappropriate activities in these response path-
ways—but toxicity is clearly not a perturbation within the range
of normal homeostatic responses.
Additional events in these pathways may be measurable be-
cause they are represented by one or more biomarkers. The mea-
surable events further along the pathway that lead to, and are
experimentally or toxicologically associated with and necessary
for the adverse outcome are also, by deﬁnition, key events—empir-
ically measurable precursor steps and necessary elements of the
AOP/MOA.
MOA differs from mechanism, in that the latter implies a more
detailed understanding of the molecular basis of the toxic effect
(Seed et al., 2005; USEPA, 2005). As part of an MOA, key events
need to be linked to the adverse outcome albeit without exhaus-
tive detail (USEPA, 2005). Knowledge of the MOA/AOP and rele-
vant biological pathways (TPs) will be needed for interpretation
of assay results. For example, one could consider the assay results
as providing information on key events at different points along
the pathway; upstream or proximal events might sufﬁce for pri-
ority setting, and information about downstream events would
be more closely related to the overall adverse outcome. Therefore,
assay results reﬂecting both upstream and downstream events in
the MOA/AOP would be critical to providing conﬁdence in an
evaluation, especially when used for hazard prediction to sup-
port a risk management action and not just for screening/
prioritization.
One of the most signiﬁcant challenges facing development of
AOPs is integration of toxicokinetics within the toxicodynamic por-
tions of the AOP. Absorption, distribution, metabolism and excre-
tion (ADME) determine the concentration of active molecule at
the target site, and this target concentration is the key to under-
standing dose response at a molecular, cellular, organ system, or
organismal level.
The dynamics of ADME can be complex. For example, some sub-
stances may be detoxiﬁed to inactive substrates by glucuronida-
tion during ﬁrst pass metabolism following oral exposure. For
other substances, the parent compound may be inactive, but
metabolism results in generation of an active metabolite, which
can then interact with biological macromolecules. Until such time
as AOPs include ADME components, conﬁdence in the predictive
value of AOPs for apical toxicity must be tempered.3. Applying the IOM, 2010 strategy to develop scientiﬁc
conﬁdence in HT/HC assays and prediction models
Validation cannot be performed in vacuo but should consider
both the biological context and intended purpose; consideration
of both is critical to ensure appropriate interpretation and use of
the data. To this end, the validation scheme outlined in the report
from the Institute of Medicine, Evaluation of Biomarkers and Surro-
gate Endpoints in Chronic Disease (IOM, 2010) provides a useful
framework for application to HT/HC methods (Fig. 2A). The three
key steps for developing an evidentiary basis for the use of bio-
markers, Analytical Validation, Qualiﬁcation and Utilization (IOM,
2010), can be adapted for HT/HC methods.
Building from IOM, 2010, three steps for validation are
proposed: Analytical Validation: considering the analytical performance of
an assay;
 Qualiﬁcation: an assessment of the association of the assay with
an initial molecular event, key event or biomarker associated
with the mode of action (MOA); and
 Utilization: a contextual and weight-of-evidence analysis of the
speciﬁc and possibly quantitative use of the assay based on all
available evidence.
3.1. Analytical validation
A key principle of science is replicability—that scientists work-
ing in other laboratories can subsequently and independently ver-
ify observations and quantitative results. Ideally, analytical
validation would include an assessment of reproducibility with
testing in multiple independent laboratories. However, if assays
are proprietary or rely on unique robotics, this may create chal-
lenges for analytical validation. Nonetheless, to meet the goal of in-
ter-laboratory validation, individual assays, using the proprietary
construct, can be tested in different laboratories. It is important
to think of this aspect of analytical validation as a challenge to
be met rather than a problem to be ignored. For example, for ro-
botic assays employing a proprietary construct in 1536 well for-
mat, the same assay could be run in a 96-well format in other
labs to show the assay is valid, predicated on the assumption that
the robotic 1536 well format would not signiﬁcantly affect the as-
say. Further, the proprietary construct can be run in parallel with a
non-proprietary assay that measures substantially the same
endpoint(s).
Some have suggested that assessment of test reliability and
reproducibility from a single laboratory can provisionally be
acceptable for validation (Balls et al., 2006), as long as this limita-
tion is considered as part of a weight of evidence determination.
However, such a situation is far from ideal. Instead, a heuristic per-
formance standard approach could be employed for proprietary
methods/prediction models. A set of reference chemicals could
be established, including both positive and negative effectors for
such cases. The positive effectors would possess a speciﬁed range
of EC50s/potencies, while the reference set would also provide full
coverage of the known applicability domains. For example, for
estrogen and androgen receptor binding assays and transcriptional
activation assays, ICCVAM (2003) provides minimum procedural
standards and a standard list of compounds to be used for valida-
tion. For both proprietary and non-proprietary HT/HC estrogen and
androgen receptor binding/transcriptional activation assays, this
set of standard compounds could be used to demonstrate suitable
assay performance as a validation exercise. A suitable subset could
also be included as quality assurance standards with each set of
test articles analyzed to ascertain and document acceptable perfor-
mance of the run.
To demonstrate how this approach might be applied, we evalu-
ated the HT/HC results reported by Judson et al. (2010) for ICCVAM
reference compounds tested in ﬁve ToxCast™ Phase I assays: two
androgen receptor (AR) binding assays and three AR transcriptional
activation (TA) response assays (two agonism and one antagonism
assays). ICCVAM (2003) recommended a total of 78 reference com-
pounds for validating ER and AR binding assays and ER TA and AR
TA assays, which included a minimum subset consisting of 75%
‘‘positive’’ and 25% ‘‘negative’’ substances to assure delineation of
speciﬁcity and sensitivity. Of the ICCVAMminimum subset for val-
idating AR binding and AR TA activity, only 9 have been evaluated
by EPA in ToxCast™ Phase 1. One of these, methyltrienolone, was
often used as a positive control in each run (Reif et al., 2010). Of
the remaining eight, 5 were ICCVAM-designated positives and 3
ICCVAM-designated negatives for assessing AR binding. The Tox-
Cast™ human AR binding assay (NVS_NR_hAR) results correctly
Fig. 2. Summary of and parallels between existing strategies to develop scientiﬁc conﬁdence in HT/HC assays and prediction models. Box A summarizes the steps to develop
an evidentiary basis for the use of a biomarker, as deﬁned by the Institute of Medicine (IOM) in their 2010 report titled Evaluation of Biomarkers and Surrogate Endpoints in
Chronic Disease. Box B summarizes parallel principles outlined in OECD Validation Principles for (Q)SAR, an approach designed to allow interpretation of (Q)SAR information
for regulatory purposes. Principle 2 (an unambiguous algorithm) is not cited in this ﬁgure since it does not directly relate to the IOM strategy.
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(Table 1). Interpretation here may be somewhat complicated be-
cause the human AR binding assay (NVS_NR_hAR) was derived
from LNCaP cells which have a mutation in the ligand binding do-
main which makes the binding pocket larger and more ﬂexible
therefore, likely to lead to false positive results (Knudsen et al.,
2011). The ToxCast™ rat AR binding assay (NVS_NR_rAR) classiﬁed
all 8 compounds as negative (Table 1), including all 5 of the ICC-
VAM-designated positive agents, suggesting that this assay might
not be useful in a screen to identify compounds with true AR bind-
ing activity.
For validation of AR TA agonist activity, of the 8 ICCVAM desig-
nated compounds (7 designated by ICCVAM an negative, 1 as posi-
tive) evaluated in the ToxCast™ AR TA assays (NCGC_AR_Agonist
and ATG_AR_TRANS), both assays correctly classiﬁed the seven
negative compounds but did not identify the single positive com-
pound, linuron (Table 2). Again, interpretation may be limited be-
cause of the imbalance between positive and negative compounds
tested for this endpoint. Furthermore, in the ToxCast™ AR TA assay
for antagonist activity (NCGC_AR_Antagonist), of the 8 ICCVAMTable 1
Predictive capability of ToxCast™ high throughput androgen receptor (A
Reference substance ICCVAM designation ToxCast™ hu
Linuron + 5.1
Vinclozolin + 0.884
Atrazine + Inactive
Bisphenol A + 17.9
Methoxychlor + Inactive
Dibutylphthalate  Inactive
DEHP  Inactive
Fenarimol  Inactive
Reference substances were those recommended by ICCVAM (2003) to
that were evaluated by EPA using the competitive binding assays (NV
et al. 2010). Designation as positive (+) or negative () is based on the
deﬁned as the half-maximal activity concentrations (AC50), where ina
activity below the highest concentration (Reif et al. 2010).designated compounds, all 5 positive compounds and all 3 nega-
tive compounds were correctly classiﬁed (Table 3) suggesting a
higher degree of scientiﬁc conﬁdence in this assay.
It should be recognized that this example uses a very limited
subset of reference compounds, only 8 of the minimum 78 com-
pounds identiﬁed by ICCVAM recommended for use in validation
of in vitro endocrine disruptor screening assays. Further, ICCVAM’s
conclusion of whether a substance is positive or negative for an
endpoint for both binding and transcriptional activation, and
including agonism and antagonism, is often based on only 1 or 2
previous test results. Nonetheless, this example provides a starting
point for discussion on the analytical validity of an assay. For in-
stance, inclusion of the rat AR binding assay (NVS_NR_rAR) may
not add value to a set of HT/HC assays to be used for prioritization,
screening, or hazard identiﬁcation purposes if the assay does not
identify true positives. Given the importance of establishing scien-
tiﬁc conﬁdence in HT/HC assays focusing on evaluating the poten-
tial endocrine activity of substances, at a minimum, before the
ToxCast™ endocrine assays for estrogen and androgen activity
are used for priority setting or screening, a much more completeR) competitive binding assays using ICCVAM reference substances.
man AR assay (EC, lM) ToxCast™ rat AR assay (EC, lM)
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive
Inactive
evaluate the validity of in vitro ER and AR binding and TA assays
S_NR_hAR and NVS_NR_rAR) as part of ToxCast Phase I (Judson
ICCVAM 2006 Addendum report. Effective concentration (EC) is
ctive results are deﬁned as chemical-assay combinations with no
Table 2
Predictive capability of ToxCast™ high throughput androgen receptor (AR) transcriptional activation (TA) assays for agonist
activity using ICCVAM reference substances.
Reference
substance
ICCVAM
designation
ToxCast™ TA (multiplexed assay)
AR cis
ToxCast™ TA (reporter gene)
AR agonist
Linuron + Inactive Inactive
Vinclozolin  Inactive Inactive
Atrazine  Inactive Inactive
Bisphenol A  Inactive Inactive
Methoxychlor  Inactive Inactive
Dibutylphthalate  Inactive Inactive
DEHP  Inactive Inactive
Fenarimol  Inactive Inactive
Reference substances were those recommended by ICCVAM (2003) to evaluate the validity of in vitro ER and AR binding and
TA assays that were evaluated by EPA using the transcriptional activation assays (NCGC_AR_Agonist and ATG_AR_TRANS) as
part of ToxCast Phase I (Judson et al. 2010). Designation as positive (+) or negative () is based on the ICCVAM 2006
Addendum report.
Table 3
Predictive capability of ToxCast™ high throughput androgen receptor (AR) transcriptional activation (TA) assays for antagonist
activity using ICCVAM reference substances.
Reference substance ICCVAM designation ToxCast™ Txn activation (reporter gene)
AR antagonist(EC, lM)
Linuron + 57
Vinclozolin + 27
Atrazine  Inactive
Bisphenol A + 73
Methoxychlor + 17
Dibutylphthalate  Inactive
DEHP  Inactive
Fenarimol + 40
Reference substances were those recommended by ICCVAM (2003) to evaluate the validity of in vitro ER and AR binding and
TA assays that were evaluated by EPA using the transcriptional activation assays (NCGC_AR_Antagonist) as part of ToxCast
Phase I (Judson et al. 2010). Designation as positive (+) or negative () is based on the ICCVAM 2006 Addendum report.
Effective concentration (EC) is deﬁned as the half-maximal activity concentrations (AC50), where inactive results are deﬁned
as chemical-assay combinations with no activity below the highest concentration (Reif et al. 2010).
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the results publicly disseminated. Furthermore, an assessment of
the concordance of results from assays aimed at measuring the
same fundamental events should also be considered. Disconcor-
dant outcomes may provide insight as to what other factors are
inﬂuencing the measured response in assay results expected to
be similar. In Phase 2 of ToxCast (data not yet released), it appears
EPA is running approximately 20 additional ICCVAM-recom-
mended endocrine active substances. Analyses of these results will
be an important addition to the existing limited data set, and will
be critical in building the necessary scientiﬁc conﬁdence in these
methods for potential future applications in priority setting and
screening.
3.2. Qualiﬁcation
In every biological pathway that begins with an IME, each and
every step will have a dose response (e.g., Ong et al., 2010). Each
subsequent step will likely depend on the response level and dura-
tion of the prior step and will likely be less sensitive to the IME
than the prior step. This initial sensitivity to perturbation is the
very essence of biological response and initial sensitivity of the
pathway is an adaptive feature that provides the organism with
information. Within each pathway, downstream homeostatic con-
trols will tend to dampen and modulate the effect of initiating
event as the system attempts to maintain the normal state.
Qualiﬁcation is the assessment of the association of the assay
with an IME, key event or biomarker associatedwith themode of ac-
tionwhereby a substance can cause an adverse response. By anchor-
ing the HT/HCmethods to a biological response pathway, the health
outcome of concern is linked to the initiating event—this is the basis
of the MOA or AOP. However, the nature of the subsequentdownstreameventswill likely tend to lessenandmodulate the effect
of the IME. Thus, a speciﬁc assay response level itselfmaynot predict
an adverse health outcome in vivo, depending on where the key
event measured by the assay occurs within the AOP.
Qualiﬁcation of the assay results would consider the context in
which to interpret the generated data. A purely empirical predic-
tion model using assay results is far from ideal (e.g., Thomas
et al., 2012). The overall interpretation would likely involve: (1)
an assessment of how well the assay results represented changes
in a biomarker and the key events with which the biomarker is
associated; and (2) a validated prediction model that incorporates
details of dosimetry, bioavailability, ADME, and other relevant fac-
tors. The data evaluation procedures should describe how assays
that examine components of an AOP can be interpreted in a man-
ner which enables inference of the toxicity processes of ultimate
concern.
Dosimetry and ADME are vital to consider for Qualiﬁcation of
assay results. For example, Reif et al. (2010) examined the Tox-
Cast™ results of 309 chemicals as a proof-of-concept exercise for
use as a decision-support tool for the Endocrine Disruptor Screen-
ing Program. Using the ToxPi visualization tool (ibid), where the
sum of responses for each group of assays that form a slice of the
‘‘pie’’ is normalized to the highest score of the set of chemicals
tested, not to a ﬁxed, external reference set of standards, Bisphe-
nol-A (BPA) received the highest normalized score (1.0) on the
estrogenicity component (6 assays) and a normalized score of 0.4
(37th of 309) on the XME/ADME component (36 assays). However,
in vivo, following environmentally relevant oral exposures to BPA,
appreciable concentrations of free BPA in blood or tissues do not
occur because it is almost completely conjugated to glucuronide
in ﬁrst pass metabolism occurring in enterocytes and the liver
(Willhite et al., 2008; Hengstler et al., 2011). The glucuronidated
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(Matthews et al., 2001). Currently, none of the assays in the XME/
ADME component measure glucuronidation. Inclusion of an assay
for glucuronidation of phenolic chemicals such as BPA would allow
a better understanding of potential biological response or lack
thereof for such substances because glucuronidated substances
have much lower afﬁnities for binding to ER or AR receptor sites,
compared to parent compounds (Zhang et al., 1999). At the present
time, how this knowledge of glucuronidation, or for that matter
how the XME/ADME component, would be used quantitatively
for inferring in vivo mediated responses remains unclear. Such
information could certainly be used qualitatively and in designing
subsequent in vivo evaluations. Most of the assays in ToxCast™
lack metabolic activity, which creates signiﬁcant challenges for
predicting potential in vivo activities, since some substances re-
quire metabolic activation to form the toxic moiety, and for others,
the parent compound is the active chemical, with metabolism
resulting in inactivation. Indeed for some chemicals, both the par-
ent compound and the metabolite(s) may contribute to the toxic-
ity. While endpoints for ‘‘estrogenicity’’ in the ToxCast™ assays
may be suitable at some point for priority setting for further eval-
uation, in the absence of additional data, they cannot be used to in-
fer an outcome.
Knowledge of the MOA, TP, AOP or biological response pathway
that is represented by a given assay within an HT/HC suite and
knowledge of human dosimetry (ADME) are both critical for Qual-
iﬁcation of an assay, especially if the assay is used for purposes
other than simple priority setting. In summary, to be able to use
the assay results in context, one would wish to test two hypotheses
during the process of method validation: (1) whether a chemical
known to produce an adverse outcome also produces a change in
relevant HT/HC biomarkers for the key events; and (2) whether
the data frommeasurements of these biomarkers can be integrated
into a model that predicts the biological response of interest and
that includes appropriate evaluation or delineation of ADME.
Addressing these two hypotheses is the essence of Qualiﬁcation
as deﬁned in IOM (2010).
The degree of Qualiﬁcation will depend on the intended pur-
pose. For the purpose of prioritization in which the objective is
to screen substances in order to select a subset for further evalua-
tion, Qualiﬁcation might be based on the observed assay results
known to reﬂect the IME and the use of a relatively simple predic-
tion model (e.g., Wetmore et al., 2011). However, even this most
simplistic use for priority setting may be problematic if ADME is
not considered. If ADME is not included, substances requiring met-
abolic activation for effects could be overlooked and substances for
which the active parent compound is rapidly metabolized to an
inactive moiety could be mischaracterized. For hazard identiﬁca-
tion purposes, particularly those related to classiﬁcation and label-
ing decisions, additional tests, even in vivo animal bioassays, would
be required. Since it appears that many of the HT/HC test methods
are focused on measuring early events in the AOP, such as the IME,
these methods are currently most suitable for priority setting and
not for hazard prediction.
Qualiﬁcation to establish the applicability of the results for a
speciﬁc use will require the determination of appropriate quantita-
tive cut-off levels for designation of a substance as, for example,
‘‘positive,’’ ‘‘negative’’ or ‘‘equivocal.’’ Therefore, the prediction
model used for a particular intended purpose will need to be devel-
oped and appropriately evaluated.
3.3. Utilization
The difference between Qualiﬁcation and Utilization is the level
of quantitative knowledge about the biological response pathway.
Utilization requires both a contextual understanding of the assayand a weight-of-evidence analysis of the speciﬁc use of the assay,
based on all available evidence, for use in making qualitative or
quantitative predictions. For the Utilization of HT/HC data as the
basis of hazard prediction, a quantitative relationship between
the (1) HT/HC results, (2) at least one biomarker of effect, and (3)
the apical adverse effect must be known with a deﬁned and likely
high level of correlation/association.
Much more additional research is needed to gain conﬁdence in
the use of HT/HC assays and batteries for predicting adverse ef-
fects. It would also be desirable to have measurable dose-related
events at the assay/biochemical, cellular, organ, organismal, and
population levels along with a biological understanding of the rela-
tionship of key events at these four levels (e.g., Akahori et al.,
2008). In addition, a validated dosimetry model to translate these
results into projected human exposure levels is needed.
These dose-related events at multiple levels of biological orga-
nization would then become key events within the MOA or part
of a well-documented AOP. Indeed, it is this knowledge of the
MOA that will enable Utilization of the assay results with scientiﬁc
conﬁdence for hazard prediction.
As more knowledge of the MOA is gained, organization of this
knowledge and the relevant assay results within an AOP frame-
work will permit inclusion of other types of data such as non-
HT/HC assay results, read-across, (Q)SAR or human or animal bio-
markers (Doull et al., 2007; Sobus et al., 2011). One fortunate con-
sequence of attaining the level of knowledge of the MOA needed to
interpret HT/HC data is that these data can in turn ameliorate
knowledge of the MOA. Hence, the results of HT/HC assays can
be used in an iterative fashion to advance the state of biological
knowledge of the AOP, TP or MOA and to better understand the
dose–response of the apical effect.4. Applying the OECD, 2007 (Q)SAR Validation Strategy to
Develop Scientiﬁc Conﬁdence in HT/HC Assays and Prediction
Models
Another validation approach that merits consideration is the
OECD Validation Principles for (Q)SAR. This approach was designed
to provide a framework for interpreting (Q)SAR information in the
context of regulatory purposes, and the ﬁve principles offer a com-
parable and additional perspective of how to validate and interpret
assays and data from emerging technologies (Worth et al., 2005;
OECD, 2007). HT/HC assays are similar to (Q)SAR models—both
are used to develop predictions of the biological activity of a given
chemical or set of chemicals.
To provide transparency and increase scientiﬁc conﬁdence in the
use of (Q)SAR methods, each method should provide information
and documentation for the following ﬁve validation principles:
1. A deﬁned endpoint.
2. An unambiguous algorithm.
3. A deﬁned domain of applicability.
4. Appropriate measures of goodness-of-ﬁt, robustness and
predictivity.
5. A mechanistic interpretation, if possible.
Prior to any application in either regulatory programs and/or
product stewardship scenario, a key requirement will be adequate
characterization of the method, whether (Q)SAR models or HT/HC
assays, in terms of performance, domain and mechanistic rele-
vance. Some of the (Q)SAR principles are more relevant to assay
performance whereas others more relevant to the prediction mod-
el used to interpret the results.
(Q)SAR Principles 1 and 4 show parallels with ‘‘Analytical
Validation’’ (Fig. 2) in terms of quantifying and characterizing the
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inate between activity/non-activity and/or potency? Indeed, the
assessment of assay performance characteristics mirrors principle
4—‘‘appropriate measures of goodness-of ﬁt, robustness and pre-
dictivity’’. This is no more than common sense; any assay method
needs to have associated with it some measure of reliability, repro-
ducibility and robustness for discriminating activity/inactivity as
well as potency.
Principles 1 and 5 mirror ‘‘Qualiﬁcation’’, assuring that there is a
deﬁned endpoint or key event for which data are being generated
and that the assay ﬁts in the context of the overall MOA or AOP—
the assay must generate information pertinent to downstream
events. Suchmechanistic relevance is essential to provide the appro-
priate biological anchor within the framework of an MOA or AOP.
Finally, Principle 3 addresses the domain of applicability of the
assay—in what circumstances or conditions, to what purpose, and
for which chemicals, can the assay provide critical information to
understand the degree of conﬁdence one can assign to a particular
interpretation of the data. It is also essential to appreciate the
scope of the chemical landscape to which the assay is applicable.
This will also be relevant for determining the applicability domain
for a given MOA, TP or AOP and permit the development of toxico-
logically meaningful chemical categories.
Together these components are pertinent to help determine
what decisions an individual assay and associated predictionmodel
result can reliably support. Different purposes for assay results may
allow different levels of uncertainty/conﬁdence. As part of an over-
all strategy to address chemical hazard, (Q)SAR data need to be val-
idated in a manner appropriate to their use (Eriksson et al., 2003).
For example, the task of rank ordering and prioritizing chemi-
cals for a subsequent and more detailed toxicity evaluation would
conceivably permit a higher degree of uncertainty than would the
use of results for hazard prediction and regulatory actions resulting
in signiﬁcant risk management actions. This difference is also mir-
rored in the (Q)SAR world in terms of whether all 5 principles are
adequately addressed and the result of a given (Q)SAR can be used
as the sole evaluation, or whether the results are sufﬁcient only as
supporting information in a weight of evidence approach (ECHA,
2008; Worth et al., 2007).
With respect to HT/HC assays, these ﬁve principles could be
readily adopted as a standard of practice. In which case developers
of such methods would be expected to provide transparent docu-
mentation in the public domain regarding the extent to which a gi-
ven method does, or does not, adhere to each of these principles. In
this manner, those relying on the results of such methods would
have a clearer understanding of the scientiﬁc applicability, limita-
tions and robustness of a method.5. Review, endorsement and communication of validation
results
In addition to having conﬁdence in the assay results and predic-
tions, end users need to be able to access the information easily. Pos-
sibilities for achieving these aims include publication in the peer
reviewed literature, evaluation by an independent science advisory
board, or an approach similar to the Cochrane Collaboration that
would provide systematic review of assay results and their use for
speciﬁc purposes (Chalmers, 1993; Chalmers andHaynes, 1994). This
last possibility may suggest a role for the Evidence-Based Toxicology
Collaboration Consortium (see ebtox.com for further information).6. The path ahead
The difﬁculty with interpretation of in vitro and in silico toxicity
evaluation is highlighted by Thomas et al. (2012), in which theToxCast™ Phase I data were evaluated comprehensively; the pre-
dictive performance of more than 600 in vitro assays was examined
across 60 in vivo endpoints using 84 different statistical classiﬁca-
tion methods. In addition, the predictive power of these models
was compared with that of QSAR and chemical descriptors. The
predictive power of the in vitro assays was not signiﬁcantly differ-
ent than that of the chemical descriptors. Nonetheless, these
authors and Judson et al. (2010) suggest that the assays can be
viewed as a survey of IMEs, and that responses of some assays or
combinations of assays can be viewed as positive or negative attri-
butes for toxicity, and that it may be possible to use the combined
net of such attributes for a given chemical for prioritizing chemi-
cals for in vivo testing.
Some of the challenges with interpreting HT/HC methods for
toxicity evaluations can be overcome by focused efforts to develop
greater scientiﬁc conﬁdence in the assays and their prediction
models. The frameworks published by IOM (2010), Evaluation of
Biomarkers and Surrogate Endpoints in Chronic Disease and the OECD
Validation principles for (Q)SARs (OECD, 2007) provide appropriate
contexts to assess the robustness, domain of applicability and util-
ity of HT/HC assays and their generated data. These frameworks
are ﬂexible and can be aligned with the intended use(s) of the
methods and prediction models. Heuristic performance standards
are practical solutions to address the issue of cross-laboratory test-
ing for proprietary HT/HC assays or those which may rely on spe-
cialized robotics. Knowledge of biological response pathways is a
critical component in the validation and interpretation of HT/HC
assays and their data. Anchoring the assays and their prediction
models to speciﬁc MOAs and/or AOPs will be essential for the inte-
gration of HT/HC assay results into risk assessment and to ensure
that the prediction models are both rigorous and ﬁt for their in-
tended purpose. The uptake and acceptance of HT/HC assays and
prediction models depends in a large part on transparency, avail-
ability of data and thorough peer review of the assays and predic-
tion models. Effective communication and dissemination of this
information to end users are essential.
Using the IOM, 2007 framework as a lens for assessing the val-
idation status of HT/HC assays indicates for many of the assays, the
best that can be done is Analytical Validation. For other assays,
those focused on speciﬁc purposes and known MOAs or well-de-
ﬁned AOPs, developing the datasets necessary for Qualiﬁcation is
achievable—many of the endpoints focus on measuring the IMEs
or other early key events. Then the HT/HC assays/prediction mod-
els that meet the requirements of Qualiﬁcation would be suitable
for screening and prioritization. Although Qualiﬁcation is insufﬁ-
cient for hazard prediction, this would still result in many bene-
ﬁts—by providing a biological basis for differentiating substances
that warrant more in depth testing from those that do not.
For hazard characterization—the prediction of adverse effects—
much more additional research is needed to develop the data sets
and prediction models to meet the level of scientiﬁc conﬁdence
embodied in the concept of Utilization. This will require a better
understanding to develop the quantitative relationship among
the (1) HT/HC results, (2) biomarkers of effect, and (3) apical ad-
verse effects. When asked about the number of toxicity pathways,
Thomas Hartung opines ‘‘as the number of cellular targets and
metabolic pathways is ﬁnite, the number of PoT [Toxicity Path-
ways] should be, too. Evolution cannot have left too many Achilles
heels given the number of chemicals surrounding us and the aston-
ishingly large number of healthy years we enjoy on average’’ (Har-
tung and McBride, 2011). Although there are evolutionary and
energy constraints on the complexity of human biology (Mayr,
1982), the question of coverage by HT/HC batteries of the entire
domain of toxicity pathways remains unknown and the question
of whether these current HT/HC molecular screening programs
represent a sufﬁcient number of key components of pathways
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(Phase 1, 467 assays as of December, 2009, see Judson et al., 2010)
suggests a degree of conﬁdence that a large range of AOPs/TPs are
largely covered. However, much work is needed to align these
‘‘parts’’ with speciﬁc pathways. Moreover, as it exists today, the
ToxCast™ battery contains a considerable amount of overlap in
the genes/proteins that are measured. For example, there are 6 as-
says related to ERa: two competitive binding assays from Nova-
screen (1 human, 1 bovine), two Attagene multiple reporter
transcription factor assays (1 cis and 1 trans), and two NCGC repor-
ter gene assays (1 measuring agonist activity and 1 for antagonist
activity) (Judson et al., 2010, supplementary material). The contri-
bution of such overlap in improving predictive models remains to
be shown.
The activities of the Tox21 program, a collaboration of EPA, the
Food and Drug Administration, the National Institutes of Environ-
mental Health Sciences/National Toxicology Program, and the Na-
tional Institutes of Health Chemical Genomics Center (http://
epa.gov/ncct/Tox21/) expand test methods, to increase the number
of chemicals evaluated, to develop and evaluate new and improved
prediction models, to collaborate and to publish in peer reviewed
journals and EPA’s leadership in disseminating data via the web1
and through communities of practice2 are commendable. This open
exchange, coupled with the OECD work program for AOPs (OECD,
2011) and the International QSAR Foundation’s development of
Effectopedia3 will enable HT/HC methods, AOPs and prediction mod-
els to be developed, evaluated, reﬁned and updated as part of a glo-
bal scientiﬁc community collaboration. As these activities proceed,
application of the approaches discussed in this paper can be used
to enhance scientiﬁc conﬁdence in the assays and their prediction
models. To move forward, several actions are recommended: (1)
the MIE term should be replaced with IME; (2) drawing from the
IOM methodology and/or the OECD QSAR principles, a speciﬁc vali-
dation strategy should be developed and implemented for HT/HC as-
says and their prediction models, focused on the speciﬁc biological
response of interest and anchored to an adverse effect/response;
(3) analytical validation of HT/HC estrogen and androgen assays
should include all, or at least a substantial sub-set, of the ICCVAM
recommended positive and negative reference compounds; and (4)
to build scientiﬁc conﬁdence, data should be publicly disseminated
and assay results and prediction models should to be subjected to
independent scientiﬁc peer review.Conﬂict of interest
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